MMP2 as a prognostic biomarker for response to anti-angiogenic therapy and survival after the therapy in cancer patients

摘要

The present invention relates to the use of matrix metalloproteinase-2 (MMP2) as a prognostic biomarker for response to anti-angiogenic therapy and survival after anti-angiogenic therapy in cancer patients, and response to anti-angiogenic therapy in cancer patients and It relates to related methods of predicting or monitoring survival after the treatment. [Selection] Figure 4